For example, pentoxifylline, which downregulates TGF-β1, has attracted interest as a possible therapy for patients with scleroderma and post-RT fibrosis (61,62) and may be considered for further investigation in patients with MAs and late treatment–related morbidity. The gene discussed is TGFB1; the disease is scleroderma.